Author:

Mónica López-Barahona

Abstract

Translational research in oncology plays a pivotal role in bridging the gap between basic science discoveries and clinical applications, thereby accelerating the development of molecular diagnosis that allows to classify tumors with a molecular approach and effective cancer treatments driving to a personalized medicine. The contribution to translational research in oncology has been developed in laboratories worldwide. However, in this article, we delve into the significant contributions of European researchers in translational oncology. Through an exploration of key initiatives, collaborative efforts, and breakthrough discoveries, we highlight the transformative impact of European translational research on cancer care. From novel therapeutic targets to innovative diagnostic tools, European scientists continue to drive progress in the fight against cancer.

Introduction

Translational research in oncology involves the process of turning scientific discoveries into new or improved cancer treatments, based on the molecular profile of the tumor. It bridges the gap between basic research (understanding the fundamental mechanisms of cancer) and clinical application (developing therapies for patients). European contributions to translational research in oncology have been significant, with various institutions, researchers, and initiatives making notable advancements. Translational research serves as the cornerstone of modern oncology, facilitating the translation of scientific discoveries into tangible benefits in diagnosis and treatment for cancer patients. Europe has emerged as a powerhouse in translational oncology, with its researchers making substantial contributions across various domains, including molecular biology, immunotherapy, and precision medicine. This article aims to shed light on some of the remarkable advancements in different fields of oncology, as well as on initiatives that have emanated from the European oncology research landscape.

Molecular Profiling and Targeted Therapies

European researchers have made significant contributions to molecular oncology, advancing our understanding of cancer biology and paving the way for the development of innovative diagnostics and therapeutics. We enunciate below a brief profiles of a few named European researchers who have made notable contributions to the field:

• The discoveries of Sir Paul Nurse (United Kingdom) related to the molecular mechanisms that regulate the cell cycle had profound implications for understanding cancer development and therapy. It is remarkable his work on cyclin-dependent kinases (CDKs) and their role in controlling cell division (Nurse PM et al 1981, Nurse P et al 2002)
• The discovery of the human papillomavirus (HPV) by Harald zur Hausen (Germany) as a causative agent of cervical cancer has revolutionized our understanding of virus-induced carcinogenesis and has led to the development of HPV vaccines for cancer prevention. (zur Hausen H 1977, zur Hausen H 2000)
• The contributions of Børresen-Dale (Norway), as pioneer in the field of cancer genomics, particularly breast cancer, have elucidated the genetic basis of breast cancer subtypes and their clinical implications, leading to improved patient stratification and personalized treatment approaches. (Børresen AL et al 1992, Stephens PJ et al 2012)
• The contribution of Carlos Caldas (Portugal) on tumor heterogeneity and genomic profiling in breast cancer has been significant in identifying molecular subtypes of breast cancer and deciphering the underlying mechanisms driving tumor progression and therapeutic response. (Perou CM et al 2000, Curtis C et al 2012)
• The contribution of Alberto Bardelli (Italy) to understanding tumor evolution and drug resistance in colorectal cancer based on his work on circulating tumor DNA (ctDNA) and liquid biopsies has advanced the field of precision oncology and personalized cancer medicine. (Bardelli A et al 2003, Diaz LA Jr et al 2012)
• The contribution of E Charpentier (France) on CRISPR-Cas9 gene editing technology. While not exclusively focused on oncology, h has revolutionized biomedical research, including cancer research, by enabling precise genome engineering for studying cancer biology and developing novel therapies. (Jinek M, Chylinski K et al 2012, Doudna JA, and Charpentier E 2014) These researchers represent a small fraction of the many European scientists who have made significant contributions to molecular oncology. Their innovative research has not only deepened our understanding of cancer biology but has also been translated into improved diagnostics, targeted therapies, and personalized treatment strategies for cancer patients worldwide. Several European researchers have made significant contributions to our understanding of oncogenes, which are genes that have the potential to cause cancer when mutated or overexpressed. Here are a few named European researchers who have made notable contributions in this field:
• Renato Dulbecco (Italy). His early work in the 1960s contributed to the understanding of oncogenes. Along with Howard Temin, he demonstrated the existence of oncogenes in RNA tumor viruses, laying the groundwork for subsequent research on viral oncogenes and their cellular counterparts. (Dulbecco R, and Vogt M 1953, Temin HM and Mizutani S 1970)
• Michael Bishop (United Kingdom) and Harold Varmus (United States) led to groundbreaking discoveries in oncogene research. In the late 1970s and early 1980s, they identified proto-oncogenes, normal cellular genes that can become oncogenic when mutated or overexpressed. Their work culminated in the Nobel Prize in Physiology or Medicine in 1989. (Bishop JM et al 1970, Stehelin D et al 1976)
• Peter Vogt (Germany) In the 1970s, he discovered that the v-Src gene carried by Rous sarcoma virus was derived from a cellular gene (c-Src) present in normal cells. This finding provided crucial insights into the role of proto-oncogenes in normal cellular processes and their transformation into oncogenes in cancer. (Martin GS 2004, Hunter T et al 1981)
• Mariano Barbacid (Spain) who played a key role in the identification and characterization of the Ras oncogene family. In the 1980s, he led a team that discovered that mutations in the Ras genes could drive the development of various cancers, including pancreatic, colorectal, and lung cancers. This discovery highlighted the importance of Ras signaling pathways in cancer and paved the way for targeted therapies. (Parada LF et al 1892, Santos E et al 1982)
• Axel Ullrich (Germany) his research on growth factor receptors and their role in cancer drived him to identified the HER2/neu oncogene in the 1980s, an oncogene which encodes a receptor tyrosine kinase involved in breast and other cancers. This discovery led to the development of HER2-targeted therapies, such as trastuzumab (Herceptin), revolutionizing the treatment of HER2-positive breast cancer. (Coussens L et al 1985, Slamon DJ et al 1989) These European researchers, among others, have made significant contributions to our understanding of oncogenes, their role in cancer development, and their potential as therapeutic targets. Their discoveries have not only deepened our knowledge of cancer biology but have also paved the way for the development of targeted cancer therapies with improved efficacy and reduced side effects. On top of the contribution of the named researchers listed above, there are initiatives such as the European Genome-Phenome Archive (EGA) (https://ega-archive.org/) and the European Molecular Biology Laboratory (EMBL) (https://www.embl.de/) that have played instrumental roles in data sharing and collaborative research endeavors. Through comprehensive genomic analyses, European scientists have identified actionable mutations and aberrations, paving the way for the development of targeted therapies tailored to individual patients.

Immunotherapy Advancements

Immunotherapy has revolutionized cancer treatment paradigms, offering durable responses and improved survival outcomes for patients with certain malignancies. European investigators have contributed significantly to the development and optimization of immunotherapeutic approaches, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. Immunotherapy has emerged as a cornerstone of cancer treatment, harnessing the body's immune system to recognize and eliminate cancer cells. European researchers have made seminal contributions to the development and refinement of immunotherapeutic modalities, spanning immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines. Key clinical trials conducted in Europe have demonstrated the efficacy of immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in a variety of malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. These agents have transformed the treatment landscape, offering durable responses and prolonged survival in subsets of patients. Furthermore, European academic centers and biopharmaceutical companies have collaborated to pioneer CAR T-cell therapy, a groundbreaking approach that involves engineering patients' T cells to express chimeric antigen receptors targeting tumor-specific antigens. This innovative therapy has shown remarkable success in hematological malignancies, with several ongoing efforts to extend its applicability to solid tumors. (23) European researchers have played pivotal roles in advancing immunotherapy for cancer treatment, contributing to the development of innovative approaches that harness the immune system to fight cancer. Here are a few named European researchers who have made notable contributions in this field:

• Guido Kroemer (Germany) whose research on cell death mechanisms and their implications for cancer immunotherapy has made significant contributions to understanding the role of apoptosis and immunogenic cell death in shaping the tumor microenvironment and modulating the immune response against cancer. His work has influenced the development of novel immunotherapeutic strategies, including combination therapies targeting both cancer cells and the immune system. (Galluzzi L et al 2015, Vacchelli E et al 2014)
• George Coukos (Greece) has made significant contributions to cancer immunotherapy, particularly in the field of cancer vaccines and adoptive cell transfer therapies. His research focuses on understanding the interplay between the immune system and the tumor microenvironment, with the goal of developing personalized immunotherapeutic approaches for cancer patients. Coukos has also been involved in clinical trials evaluating novel immunotherapy strategies for ovarian cancer. (Disis ML et al 2019, Koneru M et al 2015)
• Laurence Zitvogel (France) whose research on the gut microbiota-immune system axis and its impact on cancer immunotherapy has revealed the crucial role of the microbiome in modulating systemic immune responses and influencing the efficacy of immunotherapy in cancer patients. Zitvogel's insights have led to the exploration of microbiome-based interventions to enhance the effectiveness of cancer immunotherapy (Gopalakrishnan V et al 2018, Routy B et al 2018)
• Sergio Quezada (Spain) whose research on T cell biology and cancer immunotherapy has made significant contributions to understanding the mechanisms of T cell exhaustion and dysfunction within the tumor microenvironment and has developed innovative strategies to overcome these barriers to immunotherapy. Quezada's work has contributed to the development of combination immunotherapy approaches for cancer treatment. (Ribas A et al 2017, Quezada SA et al 2010) These European researchers, among others, have made substantial contributions to advancing cancer immunotherapy, driving progress in the development of novel treatment strategies and improving outcomes for cancer patients worldwide.

Early Detection and Precision Diagnosis

Early detection of cancer is paramount for improving patient outcomes, as it enables timely intervention and potentially curative treatments. European researchers have been at the forefront of developing non-invasive screening methods and precision diagnostic tools to detect cancer at its earliest stages. Projects such as the European Network for Cancer Research in Children and Adolescents (ENCCA) (https://www.encca.eu/) focus on elucidating the molecular underpinnings of pediatric cancers and identifying biomarkers for early detection and risk stratification. Through collaborative efforts involving clinicians, researchers, and industry partners, these initiatives aim to translate scientific discoveries into clinical applications that benefit pediatric cancer patients. Moreover, the European Cancer Information System (ECIS) (https://ecis.jrc.ec.europa.eu/) serves as a comprehensive platform for aggregating and disseminating cancer-related data, including incidence rates, mortality statistics, and screening guidelines. By harmonizing cancer surveillance efforts across European countries, ECIS facilitates evidence-based decision-making and resource allocation for cancer prevention and control.

Collaborative Consortia and Clinical Trials

Collaboration lies at the heart of translational oncology research in Europe, as evidenced by the establishment of numerous consortia and research networks dedicated to advancing cancer research and treatment. The European Organisation for Research and Treatment of Cancer (EORTC) (https://www.eortc.org/) exemplifies this collaborative ethos, bringing together academic institutions, pharmaceutical companies, and patient advocacy groups to conduct multinational clinical trials. Through these collaborative endeavors, European researchers have conducted pivotal trials that have shaped clinical practice and regulatory approval processes. For example, landmark trials investigating novel targeted therapies and immunotherapies have provided critical evidence supporting their efficacy and safety profiles, ultimately leading to their integration into standard-of-care treatment algorithms. Furthermore, initiatives such as the Innovative Medicines Initiative (IMI) (https://www.imi.europa.eu/) facilitate public-private partnerships aimed at accelerating drug discovery and development. By pooling resources and expertise from academia, industry, and regulatory agencies, IMI consortia tackle complex challenges in oncology research, from identifying druggable targets to optimizing clinical trial design and patient recruitment strategies.

Challenges and Future Directions

Despite the remarkable progress in translational oncology, European researchers face several challenges that impede the translation of scientific discoveries into clinical applications. Funding constraints, regulatory complexities, and disparities in healthcare access pose significant barriers to innovation and equitable cancer care delivery. Addressing these challenges requires sustained investment in research infrastructure and human capital, as well as policy initiatives aimed at fostering interdisciplinary collaboration and streamlining regulatory processes. Moreover, efforts to promote data sharing and interoperability among research institutions and healthcare systems are essential for harnessing the full potential of big data analytics and artificial intelligence in oncology research and clinical practice. Looking ahead, European researchers are poised to leverage emerging technologies such as single-cell sequencing, liquid biopsy, and spatial omics to unravel the intricacies of tumor heterogeneity and therapeutic resistance. By embracing a collaborative and multidisciplinary approach, Europe can continue to drive translational advancements in oncology, ultimately improving outcomes for cancer patients worldwide.

Conclusion

Translational research in oncology represents a dynamic and evolving field, with European scientists playing a central role in shaping its trajectory. From molecular profiling to immunotherapy and early detection strategies, European contributions have significantly advanced our understanding and treatment of cancer. By fostering collaboration, innovation, and knowledge exchange, Europe is poised to remain at the forefront of translational oncology research, ultimately translating scientific discoveries into tangible benefits for cancer patients worldwide.

References

Nurse PM, Bissett Y. Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast. Nature. 1981;292(5823):558-60. DOI: 10.1038/292558a0

Nurse P. Cyclin dependent kinases and cell cycle control (Nobel Lecture). Biosci Rep. 2002;22(1):65-78. DOI: 10.1023/a:1015493604432 zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977; 78:1-30. DOI: 10.1007/978-3-642-66730-5_1

zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690-8. DOI: 10.1093/jnci/92.9.690

Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992;52(11):3234-6. PMID: 1316058

Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. DOI: 10.1038/nature11017

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. DOI: 10.1038/35021093

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-52. DOI: 10.1038/nature10983

Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003;300(5621):949. DOI: 10.1126/science.1082596

Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-40. DOI: 10.1038/nature11219

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21. DOI: 10.1126/science.1225829

Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. DOI: 10.1126/science.1258096

Dulbecco R, Vogt M. Some problems of animal virology as studied by the plaque technique. Cold Spring Harb Symp Quant Biol. 1953; 18:273-9. DOI: 10.1101/sqb.1953.018.01.025

Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature. 1970;226(5252):1211-3. DOI: 10.1038/2261211a0

Bishop JM, Levinson WE, Quintrell N, Sullivan D, Fanshier L, Jackson J. The low molecular weight RNAs of Rous sarcoma virus. I. The 4 S RNA. Virology. 1970;42(3):182-95. DOI: 10.1016/0042-6822(70)90336-4

Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976;260(5547):170-3. DOI: 10.1038/260170a0

Martin GS. The road to Src. Oncogene. 2004; 23(48):7910-7. DOI: 10.1038/sj.onc.1208158

Hunter T, Cooper JA. Viral oncogenes and Src. Trends Biochem Sci. 1981;6(7):197-200. DOI: 10.1016/0968-0004(81)90250-9

Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982;297(5866):474-8. DOI: 10.1038/297474a0

Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature. 1982;298(5872):343-7. DOI: 10.1038/298343a0

Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-9. DOI: 10.1126/science.2999974

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12. DOI: 10.1126/science.2470152

European Genome-Phenome Archive (EGA): https://ega-archive.org/

European Molecular Biology Laboratory (EMBL): https://www.embl.de/

Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28(6):690-714. DOI: 10.1016/j.ccell.2015.10.012

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology. 2014;3(1):e29030. DOI: 10.4161/onci.29030

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):393-401. DOI: 10.1001/jamaoncol.2018.5942

Koneru M, Schaer D, Monu N, Ayala A, Frey AB. Defective Proximal TCR Signaling Inhibits CD8+ Tumor-Infiltrating Lymphocyte Lytic Function. J Immunol. 2015;194(9):4448-58. DOI: 10.4049/jimmunol.1401768

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. DOI: 10.1126/science.aan4236

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-7. DOI: 10.1126/science.aan3706

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109-19.e10. DOI: 10.1016/j.cell.2017.08.027

Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637-50. DOI: 10.1084/jem.20091918

European Network for Cancer Research in Children and Adolescents (ENCCA): https://www.encca.eu/

European Cancer Information System (ECIS): https://ecis.jrc.ec.europa.eu/

European Organisation for Research and Treatment of Cancer (EORTC): https://www.eortc.org/

Innovative Medicines Initiative (IMI): https://www.imi.europa.eu/